S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
NASDAQ:GNTA

Genenta Science Stock Forecast, Price & News

$9.32
-0.54 (-5.48%)
(As of 01/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.28
$9.85
50-Day Range
$9.32
$11.87
52-Week Range
$8.28
$13.13
Volume
12,400 shs
Average Volume
17,940 shs
Market Capitalization
$168.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive GNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter.


Genenta Science logo

About Genenta Science

Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon(TM). Genenta Science S.p.A. is based in MILAN, Italy.

Headlines

Genenta Science (NASDAQ:GNTA) Given "Buy" Rating at Roth Capital
January 15, 2022 |  americanbankingnews.com
Genenta Science (NASDAQ:GNTA) Shares Down 1.9%
January 13, 2022 |  americanbankingnews.com
Genenta Science (NASDAQ:GNTA) Stock Price Down 4.3%
January 13, 2022 |  americanbankingnews.com
Genenta Science (NASDAQ:GNTA) Now Covered by Maxim Group
January 13, 2022 |  americanbankingnews.com
Maxim Group Begins Coverage on Genenta Science (NASDAQ:GNTA)
January 13, 2022 |  americanbankingnews.com
Genenta Science SpA(ADR)
January 12, 2022 |  reuters.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNTA
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$168.88 million
Optionable
Not Optionable

Company Calendar

Today
1/25/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

962nd out of 1,415 stocks

Biological Products, Except Diagnostic Industry

144th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Genenta Science (NASDAQ:GNTA) Frequently Asked Questions

Is Genenta Science a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Genenta Science stock.
View analyst ratings for Genenta Science
or view top-rated stocks.

What price target have analysts set for GNTA?

2 Wall Street analysts have issued 12 month price targets for Genenta Science's shares. Their forecasts range from $21.00 to $21.00. On average, they anticipate Genenta Science's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 125.3% from the stock's current price.
View analysts' price targets for Genenta Science
or view top-rated stocks among Wall Street analysts.

When did Genenta Science IPO?

(GNTA) raised $28 million in an initial public offering on Wednesday, December 15th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share.

What is Genenta Science's stock symbol?

Genenta Science trades on the NASDAQ under the ticker symbol "GNTA."

When did Genenta Science's quiet period expire?

Genenta Science's quiet period expired on Monday, January 24th. Genenta Science had issued 2,400,000 shares in its public offering on December 15th. The total size of the offering was $27,600,000 based on an initial share price of $11.50. During Genenta Science's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Genenta Science?

Shares of GNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genenta Science's stock price today?

One share of GNTA stock can currently be purchased for approximately $9.32.

How much money does Genenta Science make?

Genenta Science has a market capitalization of $168.88 million.

What is Genenta Science's official website?

The official website for Genenta Science is www.genenta.com.

How can I contact Genenta Science?

The company can be reached via phone at 39-02-2643-6639 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.